SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

A sharp rally in XTZ has drawn attention, with traders debating whether it reflects a genuine rebound and broader altcoin rotation or a coordinated social-media pump. Bulls are highlighting a potential bottom and staking-related upside, while skeptics warn that the move may reverse and point to token inflation and repeated lower highs.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

Speculation around a major upcoming partnership or AI/robotics announcement, including recurring Tesla and Nvidia rumors, is driving attention around XYO. Traders remain divided, with some expecting a breakout based on its DePIN and verified-data use cases while others argue the tokens low liquidity and repeated pump-and-dump reversals undermine the bullish narrative.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Reports that NYSE/ICE is testing Avalanche for a 24/7 tokenized-securities platform are driving attention, alongside broader institutional and real-world-asset adoption narratives. Traders are broadly bullish on the rally and potential altcoin rotation, though skeptics remain concerned about weak follow-through, token inflation, and repeated selloffs.

Gemini Space Station, Inc. is a holding company, which engages in building secure financial infrastructure for the next generation of money and markets, providing access for individuals and institutions to a financial future that is more open, fair, and secure. The firm offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini shares are drawing attention after a large Winklevoss Capital investment at a premium valuation coincided with stronger-than-expected quarterly results. Traders are debating whether the move can develop into a short squeeze, while skeptics view the funding as insiders supporting a struggling company.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Attention is centered on Ondos real-world asset tokenization narrative, with traders reacting to reports that the Senate Banking Committee advanced the CLARITY Act and debating whether clearer regulation could accelerate institutional adoption. The main counterpoint is that ONDO remains primarily a governance token until a potential fee-switch proposal creates direct value accrual for holders, leaving some traders bullish on the sector but cautious on the tokens fundamentals.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Updated NEST Phase 2 data for Agenuss BOT+BAL immunotherapy in neoadjuvant MSS/pMMR colorectal cancer is driving attention, with traders highlighting deep pathologic responses and no observed recurrences as support for the planned ROBBIN Phase 3 program. Optimism over the drugs potential and recent financing is tempered by concerns about the small, non-randomized dataset, trial timelines, dilution, and management credibility.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Attention is centered on Uniswaps reported Robinhood integration and its role as a liquidity venue for crypto and tokenized-asset trading, alongside discussion of fee-driven UNI buybacks and burns. Traders are largely bullish on the resulting volume and deflationary narrative, though others question whether the developments are priced in and point to overbought conditions and potential pullbacks.

ETF Opportunities Trust - T-REX 2X Long GME Daily Target ETF

T-REX 2X Long GME Daily Target ETF

Speculation around a short squeeze in GameStop has drawn attention to GMEUs 2x daily exposure, with traders highlighting elevated borrow rates, limited share availability and bullish options positioning. Others argue the swap-based structure, daily reset and tracking slippage make it a risky retail trap that can underperform GME and should not be held long term.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRides international autonomous-driving expansion, particularly the Madrid Level 4 permit and Uber partnership alongside growing WRD 3.0 ADAS deployments, is driving attention. Traders remain divided: bulls see commercial validation and scaling potential, while bears point to persistent losses, heavy R&D spending, and weak price action showing that expansion has not yet translated into investor confidence.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Geopolitical supply risks involving the Iran conflict, Strait of Hormuz and Saudi pipeline disruptions are driving elevated crude prices and renewed interest in Exxons upstream earnings and cash flow. Traders remain divided between bullish views that prolonged disruptions will support energy shares and caution that ceasefire talks, repaired infrastructure or weaker demand could unwind the oil premium.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for May 27th

GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.

Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of +16.67% and -33.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Gyre Therapeutics (NASDAQ:GYRE) Trading Up 2% - Should You Buy?

Gyre Therapeutics (NASDAQ:GYRE) Trading 2% Higher - Here's What Happened...

Gyre Therapeutics (GYRE) to Release Earnings on Tuesday

Gyre Therapeutics (NASDAQ:GYRE) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...

Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell

Zacks Research lowered shares of Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday...

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Time to Sell?

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Should You Sell...

Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) posted its earnings results on Thursday. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The...

Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The firm operates two distinct segments: Gyre Pharmaceuticals and Gyre. The Gyre Pharmaceuticals segment extends three major commercial drug products including ETUARY, Etorel, and Contiva as well as several product candidates in preclinical and clinical development. The Gyre segment consists of the development and commercialization of Hydronidone for the treatment of metabolic dysfunction-associated steatohepatitis associated liver fibrosis. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Gyre Therapeutics Inc

Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.12	--	--	N/A
Q2 '26	-$0.06	-$0.12	-111.76%	MISSED
Q1 '26	-$0.07	-$0.10	-36.36%	MISSED
Q4 '25	$0.06	-$0.02	-135.29%	MISSED
Q3 '25	$0.03	$0.03	12.50%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

GYRE Earnings

Upcoming Earnings: Q3 '26

Historical Earnings